证券研究报告 宏观点评报告 / 2025.11.27 核心观点 ❖ 工业企业利润增速为何回落：10 月，工业经营量降价升、利润率回落，工 业利润增速的"恶化"，除了利润率的掣肘，与基数也有较大关系。去年"926 "政治局会议后，随着政策的加码，工业生产、消费、物价均有好转，也带动 工业利润边际修复，推高了今年四季度的基数，对同比读数形成拖累。 ❖ 分结构来看： 请阅读最后一页的重要声明！ 剔除基数，利润仍弱 分析师 张伟 SAC 证书编号：S0160525060002 zhangwei04@ctsec.com 联系人 连桐杉 liants@ctsec.com ❖ 上游采矿业仍然是"增利不增收"，与"反内卷"的推进有一定关系。多数采 矿行业营收仍然保持较大幅度的下滑，尤其是煤炭开采和非金属矿采选，10 月营收当月增速为-13.9%和-23.9%，分别较前值下滑 0.3 和 7.9 个百分点。 但采矿业利润率整体较高，近三个月均在所有行业的前列，例如有色采选和 油气开采 10 月利润率分别为 27.6%和 23.7%。在"反内卷"推进的过程中， 上游行业的减产修复了供需格局、提高了销售价格，但同时也影响销售规模。 ...

"IP+大店+体验"，重构零售渠道 名创优品(09896) 证券研究报告 商贸零售 / 公司跟踪研究报告 / 2025.11.27 投资评级:增持(维持) | 基本数据 | 2025-11-26 | | --- | --- | | 收盘价(元) | 38.14 | | 流通股本(亿股) | 12.38 | | 每股净资产(元) | 8.50 | | 总股本(亿股) | 12.38 | 最近 12 月市场表现 -20% -7% 5% 17% 29% 41% 名创优品 恒生指数 分析师 耿荣晨 SAC 证书编号：S0160525070002 gengrc@ctsec.com 分析师 杨澜 SAC 证书编号：S0160525080003 yanglan@ctsec.com 相关报告 数据来源：wind 数据，财通证券研究所（以 2025 年 11 月 26 日收盘价计算） 请阅读最后一页的重要声明！ ❖ 场景化+策展式大店重构消费体验。乐园系大店凭借 IP 沉浸式体验拉升品 牌价值，涵盖三大核心店态。1）MINISO LAND：门店面积 1000-2000 ㎡， IP 产品占比 70- 80%。以 "城市 IP 沉 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a revenue of 247.8 billion yuan for FY2026Q2, representing a year-on-year growth of 5%, slightly exceeding market expectations. Excluding high-end retail and Yintai, the same-store revenue growth was 15% [7] - The core e-commerce segment showed a significant increase, with a 15.5% year-on-year revenue growth in Q3 2025. The customer management revenue also grew by 10% year-on-year, aligning with market expectations [7] - The cloud business is entering an accelerated growth phase, with a 34% year-on-year revenue increase, surpassing Bloomberg's forecast of 28%. AI-related revenue continues to grow at triple-digit rates [7] - The company is expected to achieve revenues of 1,039.89 billion yuan, 1,137.30 billion yuan, and 1,262.70 billion yuan for the fiscal years 2026, 2027, and 2028, respectively [7] Financial Performance Summary - Revenue projections for the upcoming years are as follows: - 2024A: 941,168 million yuan - 2025A: 996,347 million yuan - 2026E: 1,039,890 million yuan - 2027E: 1,137,296 million yuan - 2028E: 1,262,700 million yuan [6] - The projected net profit for the same years is: - 2024A: 79,741 million yuan - 2025A: 129,470 million yuan - 2026E: 120,305 million yuan - 2027E: 152,779 million yuan - 2028E: 189,139 million yuan [6] - The company’s EPS is projected to be 4.10 yuan for 2024A, increasing to 9.91 yuan by 2028E [6] Market Performance - The company has shown a market performance of -6% over the last 12 months, while the Hang Seng Index has increased by 20% [4]

Investment Rating - The report maintains a "Positive" investment rating for the Robotaxi industry [1]. Core Insights - Xiaoma Zhixing has achieved single-vehicle profitability in Guangzhou, with a revenue of $60.88 million for the first three quarters, including $9.95 million from Robotaxi, representing a year-on-year increase of 112%. The company aims to reach 1,000 vehicles by the end of the year and plans to expand to over 3,000 vehicles in 2026, with a 20% reduction in BOM costs for the seventh-generation autonomous driving suite [3]. - WeRide has seen significant revenue growth, with a total of 371 million RMB and 97 million RMB from Robotaxi, marking a year-on-year increase of 457%. The company is expanding its presence in the Middle East, with 150 Robotaxis currently operating in Abu Dhabi, expecting to grow to tens of thousands by 2030 [3]. - Tesla and Waymo are accelerating their city launch plans, with Tesla obtaining a TNC license in Arizona and completing self-certification in Nevada. Waymo has updated its expansion to include cities like Houston and Orlando [3]. - The report recommends investing in Xiaoma Zhixing (PONYO), Horizon Robotics-W, and XPeng Motors-W, while suggesting to monitor Tesla, Qianli Technology, Didi Global, Uber, Cao Cao Mobility, and Ruqi Mobility [3]. Summary by Sections - **Market Performance**: The report notes a recent market performance of -7% for the automotive sector compared to the CSI 300 index [2]. - **Company Performance**: Xiaoma Zhixing and WeRide are highlighted for their strong revenue growth and operational advancements in the Robotaxi sector [3]. - **Investment Recommendations**: The report suggests a focus on domestic companies with high revenue growth and rapid commercial progress, alongside international players expanding their operations [3].

估值有支撑，关注"更高阶"低估 证券研究报告 固收定期报告 / 2025.11.26 核心观点 相关报告 1. 《城投 2026，风偏分化？》 2025- 11-25 2. 《2026 年度策略：经济 K 型复苏，股债 K 型交易》 2025-11-24 3. 《信用 | 年末或有一定波动 》 2025- 11-23 请阅读最后一页的重要声明！ 分析师 孙彬彬 SAC 证书编号：S0160525020001 sunbb@ctsec.com 分析师 隋修平 SAC 证书编号：S0160525020003 suixp@ctsec.com 分析师 李浩时 SAC 证书编号：S0160525080002 lihs@ctsec.com 联系人 郑惠文 zhenghw01@ctsec.com 联系人 柳婧舒 liujs@ctsec.com ❖ 2026 推动转债走强的"固收资产荒"以及"权益高景气"或延续。一 方面，转债整体股性处于历史高点。基于我们 2026 年年度策略的观点，我们 认为 2026 年股债双牛依然可以期待，权益有较大的想象空间，强权益或成为 2026 年转债表现最重要的支撑。另一方面，结合长端利率保持低 ...

商业航天司设立，助力产业资源战略统筹 国防军工 证券研究报告 行业投资策略周报 / 2025.11.25 投资评级:看好(维持) 最近 12 月市场表现 -11% -3% 5% 13% 21% 29% 国防军工 沪深300 分析师 佘炜超 SAC 证书编号：S0160522080002 shewc@ctsec.com 分析师 杨博星 SAC 证书编号：S0160525060005 yangbx@ctsec.com 联系人 任子悦 renzy01@ctsec.com 相关报告 1. 《福建舰正式入列，太空算力开启航天新 叙事》 2025-11-12 2. 《国防军工 2025 年三季报总结》 2025-11-05 3. 《载人任务发射成功，低空基建迎政策红 利期》 2025-11-04 核心观点 请阅读最后一页的重要声明！ ❖ 国防军工行业行情回顾：近一周(2025/11/15-2025/11/22)国防军工行业 指数涨跌幅(-1.72%)在申万一级行业中排名第 4/31；近一月(2025/10/22- 2025/11/22)国防军工行业指数涨跌幅(-3.82%)在申万一级行业中排名第 21/31；近一年(20 ...

Investment Rating - The report indicates a positive outlook for the humanoid robot industry, suggesting it is a promising investment opportunity with significant growth potential in the coming years [1]. Core Insights - The humanoid robot sector is expected to see mass production starting in 2026, with projected output levels of 50,000 to 100,000 units [2][9]. - The report highlights that the first wave of market momentum was driven by Elon Musk's announcement regarding production targets, while the second wave was influenced by a performance at the Spring Festival Gala [2][10]. - The overall market size for humanoid robots could reach 140 billion yuan if large-scale production of 1 million units is achieved, with an estimated cost of 140,000 yuan per unit [3][19]. - The industrialization of humanoid robots is accelerating, with major companies like Unitree Technology and UBTECH Robotics securing significant orders and preparing for IPOs [4][34]. Summary by Sections Humanoid Robot Market Review and Outlook - The report reviews the 2025 market performance, noting two key phases of growth driven by high-profile announcements and events [2][9]. - Future catalysts include the release of Tesla's Optimus Generation 3 and the anticipated IPOs of domestic companies [10][22]. Humanoid Robot Price and Volume Analysis - The report estimates that the cost structure of humanoid robots will see a breakdown with significant portions attributed to linear and rotational actuators [19][20]. - The market is expected to grow substantially with mass production, indicating a clear path for industrialization [22]. Acceleration of Humanoid Robot Industrialization - Major players in the industry are ramping up production capabilities and securing large orders, indicating a robust growth trajectory [4][29][31]. - The report identifies three categories of domestic players: established robot manufacturers, automotive companies, and internet giants, each leveraging their strengths in the humanoid robot space [23]. Investment Recommendations - The report suggests focusing on companies with strong order visibility and significant value in the supply chain, such as Top Group and Sanhua Intelligent Control [5][38]. - It also highlights the importance of monitoring core component suppliers that have secured orders or are undervalued [5][38].

灯塔引领品质房企，精益求精笃行向上 建发国际集团(01908) 证券研究报告 房地产开发 / 公司深度研究报告 / 2025.11.24 投资评级:买入(首次) | 基本数据 | 2025-11-24 | | --- | --- | | 收盘价(元) | 16.95 | | 流通股本(亿股) | 22.40 | | 每股净资产(元) | 13.14 | | 总股本(亿股) | 22.40 | 最近 12 月市场表现 -19% -4% 12% 28% 44% 60% 建发国际集团 恒生指数 房地产开发 分析师 房诚琦 SAC 证书编号：S0160525090002 fangcq@ctsec.com 分析师 何裕佳 SAC 证书编号：S0160525090001 heyj@ctsec.com 分析师 陈思宇 SAC 证书编号：S0160525090008 chensy04@ctsec.com 相关报告 核心观点 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | -- ...

Core Insights - The pharmaceutical MNC supply chain has extremely high entry barriers, requiring years for supplier certification through cross-departmental audits in technology, quality, EHS, and compliance. Once included in the qualified supplier list, a strong lock-in effect is formed, making it difficult for new entrants to disrupt the existing supply structure even if they meet technical standards, thus demonstrating a strong first-mover advantage [4][7]. - MNCs demand far more than conventional quality compliance, emphasizing full-process controllability and risk management capabilities. Compliance with guidelines such as EU GMP and ICHQ is required, along with the establishment of traceability systems and safety stock. Any process changes or relocation of production sites must undergo strict and time-consuming certification [4][7]. - In procurement decisions, MNCs are relatively insensitive to price factors, prioritizing the integrity of the supply chain over cost. For MNCs, API costs represent only a small portion of their terminal formulation sales, leading them to pay a premium for stable, traceable, and zero major quality incident supply capabilities, viewing supply chain resilience as a core competitive advantage rather than a cost item. Thus, entering the MNC supply chain often means effectively avoiding "price internalization" [4][7]. - Investment recommendations include innovative drug and device companies such as Furuya Co., Aonlikang, Shutaishen, Weichuang Bio, and others. From the perspective of CXO and raw materials, companies like WuXi AppTec, Jiuzhou Pharmaceutical, Chengda Pharmaceutical, and others are suggested for attention [4][7]. Market Performance Overview - As of November 21, 2025, the TTM-PE of the pharmaceutical and biotechnology industry is 48.84 times, which is 100% higher than the historical lowest PE valuation of 24.38 times on January 3, 2019. The premium rate relative to the CSI 300 is 252%, exceeding the historical lowest valuation premium of 124% on February 6, 2018, by 128 percentage points, and is 11 percentage points higher than the average valuation premium rate of 241% over the past decade [8][12]. - From November 17 to November 21, 2025, the pharmaceutical and biotechnology sector experienced a decline of 6.88%, ranking 22nd among 27 sub-industries. The chemical raw materials sector saw the largest decline at -8.60% [12][15]. Industry Dynamics - Pfizer's Class 1 new drug, Matacizumab, was approved for marketing on November 21, 2025, for the routine prevention and treatment of bleeding in patients with severe hemophilia A or B [20]. - Boehringer Ingelheim's Class 1 new drug, BI764198, was proposed for inclusion as a breakthrough therapy on November 18, 2025, targeting primary focal segmental glomerulosclerosis [21]. - The PD-1 inhibitor H drug, Surulutumab, developed by Fuhong Hanlin, was officially included as a breakthrough therapy on November 20, 2025, for gastric cancer treatment [22]. - On November 17, 2025, FDA approved the biosimilar of Tysabri, developed by Sandoz, for multiple sclerosis and Crohn's disease [23].

Report Industry Investment Rating - No relevant content provided Core Viewpoints - The weekly technical analysis of treasury bond futures shows that the neckline of the head-and-shoulders bottom of the 30-year treasury bond futures was broken, weakening the pattern, and attention should be paid to the subsequent repair strength. TL2603 fell back after a rebound and is in a short-term adjustment. If it further declines after the repair, subsequent market conditions need to be dealt with cautiously [1]. - The data tracking of treasury bond futures indicates that the main contract is about to change, and the cash-and-carry strategy of the 2603 contract still has some participation value. This week, the performance of treasury bond futures was differentiated, and the trading activity increased overall. The CTD net basis of the 2603 contract decreased overall, and the IRR increased except for TL. Currently, the IRR of T2603 and TL2603 is still significantly higher than the capital interest rate [2]. Summary by Directory 1. Weekly Technical Analysis 1.1 Pre - trend Review - This week, the trends of T and TL were differentiated. T rose slightly, while TL declined continuously since Wednesday. TL2603 first rose and then fell, and TL2512 broke below the upper edge of the bottom area (around 115.57) on Friday, breaking the neckline of the head-and-shoulders bottom pattern and closing near the 60 - day line [6]. 1.2 Subsequent Market Outlook - TL2603 showed signs of weakening after breaking below the neckline of the head-and-shoulders bottom on Friday. From the perspective of the wave theory, the adjustment since November 5th may form a platform type, and it may be at the end of the short - term adjustment. Attention should be paid to the repair strength. If the market declines again after the repair, the risk of further continuation of the adjustment needs to be concerned. TL2603 was weaker than T2603 this week. T2603 also broke below 115.57 on Friday, weakening the pattern. If the end of the platform type forms a phased low, the subsequent market can still be optimistic [9]. 2. Weekly Tracking of Treasury Bond Futures - This week, the performance of treasury bond futures was differentiated. As of November 21st, the closing prices of the 2512 contracts of 2 - year, 5 - year, 10 - year, and 30 - year treasury bond futures were 102.460, 105.855, 108.430, and 115.57 yuan respectively, with changes of +0.006, -0.020, +0.015, and -0.59 yuan compared with the previous week [15]. - The trading activity of treasury bond futures increased overall this week. The average daily trading volume of the 2512 contracts of each maturity increased compared with last week, and the trading volume/holding volume increased for each maturity [15]. - As of November 21st, the holding volume of the 2512 contracts of treasury bond futures decreased across the board, while that of the 2603 contracts increased across the board, indicating that participants continued to shift positions [15]. - As of November 21st, the CTD net basis of the 2603 contracts of each maturity decreased overall, with little change in TL. The CTD net basis of the 2512 contracts of 2 - year, 5 - year, 10 - year, and 30 - year were -0.07, -0.05, -0.11, and -0.13 yuan respectively. In terms of IRR, the IRR of the CTD of the 2603 contracts of 2 - year, 5 - year, 10 - year, and 30 - year were 1.66%, 1.60%, 1.77%, and 1.75% respectively, increasing except for TL. The cash - and - carry strategies of T2603 and TL2603 still have some participation value. The spread between the 2512 - 2603 contracts decreased overall this week [18].